The neurobiological activity of hallucinogenic tryptamines

the full preprint containing a tryptamine index is available at


Longer Abstract Summary

Tryptamine-derived compounds, many of them hallucinogenic, have been found to be potent pharmaceutical agents1. In particular, psilocin (4-HO-DMT) and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have performed exceptionally well in controlled studies across a variety of conditions, including depression, anxiety disorders, post-traumatic stress disorder, and substance addiction, even after a single treatment.2,3 Mostly naturally occurring species have been investigated although many synthetic alternatives have the potential to offer preferable qualities including higher potency and improved valence, making them safer and more effective in the clinical setting.4,5 In this review, I describe our current knowledge of molecular and receptor circuitry involved in the hallucinogenic action of tryptamines as well as some challenges and prospects in ensuring physical and psychological safety of hallucinogenic tryptamines in the clinical setting.


Despite a large volume of research into the psychiatric applications of tryptamine and phenethylamine-derived compounds, an unfavorable political climate and broad fear over misuse in the late 1960s shut down a significant portion of further studies and academic work, despite highly promising results.6 Simultaneously, the discovery rate for new neuropharmacological small molecule agents has been exceptionally slow with few notable successes.7 As an example to illustrate this point, current rates of efficacy for the most effective antidepressant selective serotonin reuptake inhibitors (SSRIs) average below 50 percent with a significant number of drawbacks including dependency and serious side effects.8,9

Nevertheless, the last two decades have witnessed the revisiting of previously neglected compounds which have shown to be effective in treating a wide range of neuropsychiatric disorders. In particular, tetrahydrocannabinol (THC) has been used for the treatment of epilepsy, Dravet syndrome, and for the prevention of nausea caused by certain cancer medications, amongst other conditions.10 Esketamine, a glutamate receptor antagonist and enantiomer of ketamine, was found to treat depressive symptoms in patients and subsequently approved for use by the United States FDA.11

Presently, serotonologic compounds such as psilocin, DMT, and 5-methoxy-DMT have been resurrected as potential treatments for depression, anxiety, post-traumatic stress disorder, substance abuse, and personality disorders. While many of the initial results have been highly promising, challenges remain including physiological and psychological safety. While many of the compounds tested have a number of highly beneficial properties including generally low substance abuse profiles, they can also induce negative symptoms such as paranoia and cause fearful episodes.12

As the new wave of serotonological therapeutics begins to mature, it is possible structural derivatives of existing hallucinogenic compounds will play a role in improving safety, generalizability, and efficacy.13 Based on the work done by a number of medicinal chemists, chiefly among them Dr. Alexander Shulgin, a number of such derivative compounds have already been synthesized with some preliminary reports on their effects and pharmacological properties available.14,15 The lesser known compounds have relatively few controlled subjective reports and require further study while having some potentially intriguing properties.

All such compounds are variations of the indole-related tryptamine class, a parent structure shown in Figure A with substitution groups marked with R values. Serotonin (5-HT), one of the most ubiquitous neurotransmitters, is a tryptamine derivative, while certain dimethylated variants (such as DMT) are endogenous to humans and can be found in blood and cerebrospinal fluid.16

Variation in the hallucinogenic effects of each compound is a function of many variables including dosage, body weight, method of consumption, lipophilicity of the drug, structural polarity, and differential agonism against neural receptors, most notably the 5-HT class. Certain patterns of structure-based drug activity can be understood from research and reports conducted over the past several decades.17

Screen Shot 2020-06-16 at 12.28.22 PM.png
Figure A: The molecular structure of tryptamine

Activity in the primary tryptamine is highly dependent on substitutions at the R4 and R5 indole benzene positions and the RN1, RN2 and R-alpha positions on the amino-terminated chain. By contrast, preliminary work by Shulgin and others has found that substitutions at other positions on the indole structure produce primarily inhibitory effects with decreased potency and activity. Additionally, increasingly long alkylation at the RN1 and RN2 positions produces noticeably diminishing activity.

Understanding the functional differences in binding and activity between various substituted tryptamines will be an essential area of research to better understand their mechanism of action in the brain and improve safety.

Beyond simply the discovery of safer psychedelic compounds, future therapies will need to be adjusted to the needs of each patient. A single negative experience with a psychedelic drug, even in the clinical setting, could lead to aversion to future treatment. To avoid such an outcome, treatments must protect against the psychological dangers inherent in hallucinogenic drugs. Development of such treatments will require careful considerations of drug structure, activity, dosage, setting-of-treatment, time course, and other related factors.

Neural correlates of tryptamine activity

One of the many challenges in elucidating the mechanism of action of psychedelic tryptamines in the brain is the complex interrelationship between the compound, its dosage, characteristics, personality of the subject, and exterior factors such as the setting in which it is consumed.18 A decade or so after the discovery of LSD, the presence of serotonin was detected in the mammalian brain. In the late 1960s, it was hypothesized that hallucinogenic compounds may have direct agonism at the 5-HT receptors, specifically discriminating from other non-hallucinogenic compounds at the 5-HT2A receptor.19 This evidence was further strengthened by a study showing controlled inhibition of the hallucinogenic effects of psilocin by pairing it with a 5-HT2A antagonist and demonstrating functional selectivity at the 5-HT2A receptor.20

Additionally, further studies have revealed that hallucinogenic tryptamines enhance glutamatergic transmission in the cerebral cortex at both a functional neuronal level and in the context of behavioral tasks.21 It was first reported twenty years ago that 5-HT induced a rapid increase of spontaneous glutamatergic excitatory postsynaptic potentials (EPSPs)/excitatory postsynaptic currents (EPSCs) in cortical pyramidal cells of visual cortex layer V, with the most pronounced effect in areas having above normal 5-HT2A expression.22 While several theories have been proposed to explain the increase in cortical glutamate, none has thus far been definitively conclusive. Though most work on frontal cortex neurotransmitters has focused on glutamate, 5-HT2A activation was also found to increase extracellular GABA, thereby producing both excitation and a feed-forward inhibition of cortical pyramidal cells.23

Much of the initial work on such neuronal effects was performed using single cell recordings from brain slices which are often not representative of an intact and functional cortex. More recently, ultra-high field multimodal brain imaging has revealed that psilocybin induced region dependent alterations in glutamate in the prefrontal cortex and the hippocampus. Moreover, regional alteration in glutamate was predictive of both positive and negative valence in the hallucinogenic effect based on subject feedback.24

Further research on rhythmic patterns of activity originating in cortical and subcortical areas has revealed certain interesting clues. Combining opto- and pharmacogenetic manipulations with electrophysiological recordings, it was discovered that 5-HT inhibits slow oscillations within the entorhinal cortex via the activation of Som interneurons via the 5-HT2A receptor. Intravenously administered DMT reduced oscillatory power in the alpha and beta bands and robustly increased spontaneous signal diversity. Furthermore, peak effects induced the emergence of theta and delta oscillations. One possible proposed explanation involves the switching from exterior information processing to interior endogenous perception, linked to phenomena such as REM sleep.25

While a definitive mechanism of action of hallucinogens is still not apparent, existing work has elucidated some of the functional pathways on a cellular, systemic, and behavioral level. Further research into fundamental neuroscience will be required to fully uncover the picture. Figure B shows a table of known receptor Ki values (in µM) for a set of hallucinogenic tryptamines.

Screen Shot 2020-06-29 at 12.50.01 PM.png

Figure B: A table of receptor Ki values (all values are in µM) for tryptamine variants with hallucinogenic properties

Considerations for safety in the clinical use of tryptamines

The future prospects of tryptamines, both of synthetic or naturally-occuring origin will be dependent in large part on physical and psychological safety in the course of treatment. In early psychedelic research, two treatment approaches were explored: one focused on administering low doses of a hallucinogenic or empathogenic compound in the course of multiple sessions of psychoanalytic therapy; the other uses higher doses of psychedelic agents in the course of one or a few sessions to achieve a “peak” experience. While many contemporary studies showing high efficacy have utilized the latter paradigm, many experts have expressed the need for caution to mitigate the risk of negative experiences or “bad trips.” Hallucinogens known to induce “peak” experiences such as DMT, 5-MeO-DMT, and psilocin also have a documented history of negative psychological and physical side effects. Several paths for the reduction of risk could include:

–> Ensuring a comfortable and safe setting for patient infusions is kept to minimize possible stress throughout the treatment.

–> Pairing multiple compounds to reduce anxiety throughout the infusion and mitigate side effects such as nausea.

–> The development of novel tryptamine compounds which result in fewer negative valence responses.

In particular, pairing empathogens normally associated with increased valence with hallucinogenic compounds could have possible beneficial effects in the form of reduced anxiety and fear responses during treatment. Further research will be necessary to determine the efficacy and possible dangers of such approaches, notably cardiac and cross-interactivity risks.


The present review is an attempt to accomplish a few things. Firstly, it is to give a very succinct background on our existing knowledge of tryptamine activity in the brain. Secondly, it is to talk about some hurdles in the clinical use of psychedelic substances, namely physical and psychological safety and to suggest a few possible paths forward including drug discovery and combinatorial approaches. Not discussed within the review but of great importance is also the difficulty of evaluating novel tryptamines with complex visual and auditory components not usually suitable for animal models. The revolutionary potential of empathogenic and hallucinogenic substances depends not only in their effectiveness as agents but also on ensuring the safety of a broad clinical pool.


  1. Nichols, David E., Matthew W. Johnson, and Charles D. Nichols. “Psychedelics as medicines: an emerging new paradigm.” Clinical Pharmacology & Therapeutics 101.2 (2017): 209-219.

  2. Johnson, Matthew W., and Roland R. Griffiths. “Potential therapeutic effects of psilocybin.” Neurotherapeutics 14.3 (2017): 734-740.

  3. Davis, Alan K., et al. “5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.” The American journal of drug and alcohol abuse 45.2 (2019): 161-169.

  4. Andersson, Martin, Mari Persson, and Anette Kjellgren. “Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches.” Harm reduction journal 14.1 (2017): 60.

  5. Dargan, P.; Wood, D. “Novel Psychoactive Substances: Classification, Pharmacology and Toxicology.” First Edition. Academic Press. (2013).

  6. Doblin, Richard E., et al. “The Past and Future of Psychedelic Science: An Introduction to This Issue.” (2019): 93-97.

  7. Gribkoff, Valentin K., and Leonard K. Kaczmarek. “The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes.” Neuropharmacology 120 (2017): 11-19.

  8. Jakobsen, Janus Christian, et al. “Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis.” BMC psychiatry 17.1 (2017): 58.

  9. Ioannidis, John PA. “Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?.” Philosophy, Ethics, and Humanities in Medicine 3.1 (2008): 14

  10. Lim, Keane, Yuen Mei See, and Jimmy Lee. “A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders.” Clinical Psychopharmacology and Neuroscience 15.4 (2017): 301.

  11. Daly, Ella J., et al. “Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial.” JAMA psychiatry 76.9 (2019): 893-903.

  12. Ona, Genís. “Inside bad trips: Exploring extra-pharmacological factors.” Journal of Psychedelic Studies 2.1 (2018): 53-60.

  13. Riedlinger, Thomas J., and June E. Riedlinger. “Psychedelic and entactogenic drugs in the treatment of depression.” Journal of Psychoactive Drugs 26.1 (1994): 41-55.

  14. Shulgin, Alexander, and Ann Shulgin. TIHKAL: the continuation. Transform press, 1997.

  15. Sargent, T., et al. “In vivo human pharmacodynamics of the psychodysleptic 4-Br-2, 5-dimethoxyphenylisopropylamine labelled with 82Br or 77Br.” Neuropharmacology 14.3 (1975): 165-174.

  16. Barker, Steven A. “N, N-Dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function.” Frontiers in neuroscience 12 (2018): 536.

  17. Shulgin A. “Stereospecific requirements for hallucinogenesis”. J. Pharm. Pharmac. 25: (1973): 271-272. 68

  18. Nichols, David E. “Psychedelics.” Pharmacological reviews 68.2 (2016): 264-355.

  19. Woolley, Dilworth W., and E. Shaw. “A biochemical and pharmacological suggestion about certain mental disorders.” Proceedings of the National Academy of Sciences of the United States of America 40.4 (1954): 228.

  20. Glennon, Richard A., Richard Young, and John A. Rosecrans. “Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.” European journal of pharmacology 91.2-3 (1983): 189-196.

  21. Aghajanian, George K., and Gerard J. Marek. “Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release.” Brain research 825.1-2 (1999): 161-171.

  22. Aghajanian, G. K., and G. J. Marek. “Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells.” Neuropharmacology 36.4-5 (1997): 589-599.

  23. Marek, Gerard J., and George K. Aghajanian. “Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist.” European journal of pharmacology 259.2 (1994): 137-141.

  24. Mason, N. L., et al. “Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.” Neuropsychopharmacology (2020): 1-11.

  25. Timmermann, Christopher, et al. “Neural correlates of the DMT experience assessed with multivariate EEG.” Scientific reports 9.1 (2019): 1-13.

  26. Halberstadt, Adam L., David E. Nichols, and Mark A. Geyer. “Behavioral effects of α, α, β, β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.” Psychopharmacology 221.4 (2012): 709-718.

  27. Ray, Thomas S. “Psychedelics and the human receptorome.” PloS one 5.2 (2010).


Now read this

Phenethylamines I have feared and loathed

In the course of a burgeoning interest in psychedelic medicine, one comes across two broad categories of similarly interested characters. You will find that some are neurotically obsessed with rigor and refuse to even discuss what these... Continue →